E. Pierce

发表

Treatment Patterns in Danish Patients with Atopic Dermatitis Before and After Hospital Referral

J. Thyssen, A. Egeberg, Jashin J. Wu, 2021, Dermatology and Therapy.

Improvement in symptoms of anxiety and depression in patients with atopic dermatitis after treatment with baricitinib

S. Ball, P. Lio, J. Thyssen, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies

T. Buhl, E. Serra‐Baldrich, P. Fernández-Peñas, 2021, Dermatology and Therapy.

Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database

Robert J. Goodloe, J. Silverberg, R. Goodloe, 2021, Dermatology and Therapy.

Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5)

M. Casillas, D. Rosmarin, Stacy R. Smith, 2022, Journal of cutaneous medicine and surgery.

Treatment of adult atopic dermatitis patients according to disease characteristics and demographics

J. Thyssen, A. Egeberg, Y. Andersen, 2020, Dermatologic therapy.

Pyoderma Gangrenosum in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Jayesh P. Rai, R. Baumgartner, S. Galandiuk, 2020, Digestive Diseases and Sciences.

Is macrolide and beta-lactam combination therapy associated with early clinical stability or 30 day mortality in hospitalized patients with pneumonia? An assessment of confounding by indication.

E. Pierce, 2018 .

A Qualitative Analysis of Provider Notes of Atopic Dermatitis-Related Visits Using Natural Language Processing Methods

Xiong Liu, O. Goldblum, N. Boytsov, 2021, Dermatology and Therapy.

Burden of adult atopic dermatitis and unmet needs with existing therapies

A. Atwater, E. Bacci, W. Begolka, 2023, The Journal of dermatological treatment.

Prevalence, incidence and relative risk of cardiovascular disease risk factors in adults with atopic dermatitis: A systematic review

J. Silverberg, J. Thyssen, M. Feely, 2023, JEADV Clinical Practice.

Long‐term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate‐to‐severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE‐AD7

J. Silverberg, E. Simpson, T. Werfel, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long‐term efficacy and patient‐reported outcomes

J. Silverberg, E. Simpson, M. Boguniewicz, 2022, Dermatologic therapy.

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD7 Phase 3 randomized trial

J. Silverberg, K. Peris, M. Tauber, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Maintained Improvement in Physician- and Patient-Reported Outcomes with Baricitinib in Adults with Moderate-to-Severe Atopic Dermatitis who were Treated for up to 104 Weeks in a Randomized Trial.

J. Thyssen, S. Barbarot, A. Wollenberg, 2023, The Journal of dermatological treatment.

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.

J. Silverberg, T. Bieber, J. Thyssen, 2023, The British journal of dermatology.

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis

M. Witte, M. Gooderham, S. Ferrucci, 2023, JAMA dermatology.

Patient-Reported Disease Burden and Unmet Therapeutic Needs in Atopic Dermatitis.

A. Rentz, E. Bacci, W. Begolka, 2021, Journal of drugs in dermatology : JDD.

The direct and indirect costs of adult atopic dermatitis

M. Bonafede, J. Manjelievskaia, O. Goldblum, 2021, Journal of managed care & specialty pharmacy.

Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry

J. Silverberg, E. Simpson, V. Shi, 2023, Dermatology and Therapy.

Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials.

B. Piraccini, M. Ohyama, A. Bewley, 2023, The Journal of dermatological treatment.

Disease burden among patients with atopic dermatitis treated with systemic therapy for 4-12 months: results from the CorEvitas Atopic Dermatitis Registry.

J. Silverberg, E. Simpson, A. Atwater, 2023, The Journal of dermatological treatment.

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

C. Flohr, A. Paller, S. Weidinger, 2023, Dermatology and Therapy.

The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials

Luna Sun, O. Goldblum, E. Pierce, 2022, The British journal of dermatology.

Impact of Atopic Dermatitis Lesion Location on Quality of Life in Adult Patients in a Real-world Study.

J. Silverberg, J. Piercy, J. Thyssen, 2020, Journal of drugs in dermatology : JDD.

Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.

Luna Sun, D. Rosmarin, E. Pierce, 2023, The British journal of dermatology.